Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

NCT02822157 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Epithelial Cancer

Interventions

DRUG: Olaparib
DRUG: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly

Sponsor

Universitaire Ziekenhuizen KU Leuven

Collaborators

[object Object]